A comparative study to evaluate the role of Virechana and Bhringrajadi Lepa on Shwitra with special reference to Vitiligo in children
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Primary Outcome Measures- VASI Score
研究概览
简要总结
Recently rapidly increasing incidences of Shwitra is a challenge for medical world. Vitiligo is the pigmentary disorder of certain hereditary and acquired and autoimmune causes and characterized by depigmented or hypopigmented patches that results from absence or depleted in melanocytes. Pathogenesis of vitiligo points towards autoimmune hypothesis1 and disease may start at any age with increased incidences in first and second decade of life. Based on some dermatological out patient records the incidences are roughly estimated to be between 3-4% in India. However, vitiligo affects the estimated 1-2%of world population which is quite significant2. Present study has been designed to study the role of Samshodhan Karma followed by BhringrajadiLepa, externally, over the discoloured patches in children with subsequent exposure to sunlight. BhringrajadiLepa has been quoted in the classics (Bhrihad Nighantu Ratnakar by Khemraj Shri Krishna Das, Chapter-Tvagadosha,
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Open Label
入排标准
- 年龄范围
- 5.00 Year(s) 至 15.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Patient of either sex between age group of 05 -15 years 2.Children diagnosed as vitiligo as per contemporary medical science or Shwitra as per clinical features mentioned in Ayurvedic texts.
排除标准
- •1.Children below 05 and above 15 years of age.
- •2.Children with Albinism will be excluded.
- •3.White anesthetic spots, which are characteristic of leprosy will be excluded.
- •4.Old refractory cases not responding after extensive use of modern medicine will be also excluded.
- •5.One year old vitiligo patch will be excluded.
- •6.Patches in genital and lip area will be excluded.
结局指标
主要结局
Primary Outcome Measures- VASI Score
时间窗: baseline, 15th day
次要结局
- Cosmetic concern of the patient regarding depigmentation of the skin(baseline, 15th day)